Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06100133
Other study ID # NEFADPKD1
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date November 2023
Est. completion date July 2025

Study information

Verified date September 2023
Source Universitair Ziekenhuis Brussel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators are running a study to see if a special drink, called a "ketone ester", can help people with a type of kidney disease named "Autosomal Dominant Polycystic Kidney Disease" or ADPKD for short. The investigators want to find out: If it's easy for patients to take this drink every day for about 2 months. If it's safe and doesn't cause any problems. If it makes a difference in the size and function of the kidneys. Who can join? People between 16 to 70 years old who have ADPKD. Those with a certain amount of kidney size and function. People who haven't been on specific diets or lost a lot of weight recently. Women who are not breastfeeding and are using birth control. People with a body weight that is not too low or too high. Who cannot join? People who've been on a high-fat diet or skipped meals for a while recently. Those with other health conditions like diabetes or certain metabolic issues. Anyone who has a problem with getting an MRI scan. If participants are in another medical study right now. The study will happen in two Belgian hospitals and is supported by the UZ Brussel's nephrology department. The investigators hope to include 20 people and start in November 2023.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date July 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 16 Years to 70 Years
Eligibility Inclusion Criteria: - - ADPKD patients (diagnosis based on genetics or imaging) = 16 and = 70 years. - Total Kidney Volume = 600 mL. - eGFR (CKD-EPI) = 30 ml/min/1.73m2. - Normal blood glucose, HbA1C and ketones. - Women of childbearing potential who are non-lactating and using an effective form of birth control. - Stable disease-modifying treatment for the last 2 months. - Well controlled hypertension (stable antihypertensive medications for at least 2 months). - BMI > 18 < 30. - Written informed consent. Exclusion Criteria: - Exposure to a ketogenic diet or intermittent fasting for more than 2 weeks within 6 months before inclusion. - Significant weight-loss (> 10%) within 6 months before inclusion. - Diabetes mellitus. - Conditions prohibiting the use of a ketogenic diet (liver damage, pancreatic failure, pyruvate-carboxylase deficiency, defects in fatty acid oxidation/gluconeogenesis/ketolysis/neogenesis, hyperinsulinism), based on patient history. - Diagnosis with any disorder of fatty acid metabolism based on patient history. - Eating disorder. - Alcohol abuse. - Contraindication for MRI. - Participation in other interventional trial.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Ketone ester
Up to 100g ketone ester daily for 56 days

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Universitair Ziekenhuis Brussel

Outcome

Type Measure Description Time frame Safety issue
Primary Observance Objective observance (ketone body levels =0.8 mmol/l in =75% of blood measurements and =60% of maximal theoretic dose determined by used packages and self-report) 56 days
Primary Feasibility Patient reported feasibility, defined as a cohen d effect size of < 0.5 in the ADPKD impact scale.Both targets (observance and self-reported feasibility) must be met to reach the endpoint. 56 days
Secondary Total Kidney Volume Change in Total kidney volume (in mL; assessed with MRI) baseline vs day 56 56 days
Secondary Kidney Function Change in estimated glomerular filtration rate (eGFR) according to CKD-EPI; baseline vs day 56 56 days
See also
  Status Clinical Trial Phase
Recruiting NCT04310319 - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt N/A
Completed NCT02776241 - Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease N/A
Terminated NCT04152837 - Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT03717883 - ADPKD Alterations in Hepatic Transporter Function
Recruiting NCT05014178 - Kidney Sodium Functional Imaging
Recruiting NCT05521191 - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 1
Terminated NCT04064346 - Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT03203642 - Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD Phase 2
Recruiting NCT04338048 - Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
Completed NCT01632605 - The Vienna RAP Pilot Study N/A
Terminated NCT03918447 - A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON Phase 3
Recruiting NCT06416761 - Genetics in the Progression of Nephropathies
Not yet recruiting NCT05373264 - HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life Phase 3
Recruiting NCT06085807 - Genetic Testing in Autosomal Dominant Polycystic Kidney Disease
Completed NCT01853553 - Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Completed NCT04472624 - Short Term Induction of Ketosis in PKD N/A
Not yet recruiting NCT03764605 - Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT04680780 - Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD) N/A
Completed NCT02161068 - Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
Active, not recruiting NCT03273413 - Statin Therapy in Patients With Early Stage ADPKD Phase 4